Hyperspectral Retinal Imaging as a Non-Invasive Marker to Determine Brain Amyloid Status
Journal of Alzheimer's Disease · 20.08.2024 · 100 (s1) · S131-S152
DOI: 10.3233/jad-240631 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer's Disease, erschienen am 20.08.2024. Verfasst von Purna Poudel und 6 weiteren Autor:innen. Beteiligte Einrichtung: Alzheimer's Research Australia, Ralph and Patricia Sarich Neuroscience Research Institute, Nedlands, WA, Australia. Hauptthemen laut MEDLINE: Retina, Alzheimer Disease, Brain, Amyloid beta-Peptides. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 75 Literaturangaben.
Abstract (Originalsprache)
Background
As an extension of the central nervous system (CNS), the retina shares many similarities with the brain and can manifest signs of various neurological diseases, including Alzheimer’s disease (AD).
Objective
To investigate the retinal spectral features and develop a classification model to differentiate individuals with different brain amyloid levels.
Methods
Sixty-six participants with varying brain amyloid-β protein levels were non-invasively imaged using a hyperspectral retinal camera in the wavelength range of 450–900 nm in 5 nm steps. Multiple retina features from the central and superior views were selected and analyzed to identify their variability among individuals with different brain amyloid loads.
Results
The retinal reflectance spectra in the 450–585 nm wavelengths exhibited a significant difference in individuals with increasing brain amyloid. The retinal features in the superior view showed higher inter-subject variability. A classification model was trained to differentiate individuals with varying amyloid levels using the spectra of extracted retinal features. The performance of the spectral classification model was dependent upon retinal features and showed 0.758–0.879 accuracy, 0.718–0.909 sensitivity, 0.764–0.912 specificity, and 0.745–0.891 area under curve for the right eye.
Conclusions
This study highlights the spectral variation of retinal features associated with brain amyloid loads. It also demonstrates the feasibility of the retinal hyperspectral imaging technique as a potential method to identify individuals in the preclinical phase of AD as an inexpensive alternative to brain imaging.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Alzheimer's Research Australia, Ralph and Patricia Sarich Neuroscience Research Institute, Nedlands, WA, Australia.
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.
- Commonwealth Scientific and Industrial Research Organisation (CSIRO), Kensington, WA, Australia.
- Australian e-Health Research Centre, Floreat, WA, Australia.
- Lifespan Health and Wellbeing Research Centre, Macquarie Medical School, Macquarie University, Macquarie Park, NSW, Australia.
- Centre for Healthy Ageing, Health Futures Institute, Murdoch University, Perth, WA, Australia.
Zitieren
APA
Poudel, P., Frost, S. M., Eslick, S., Sohrabi, H. R., Taddei, K., Martins, R. N., & Hone, E. (2024). Hyperspectral Retinal Imaging as a Non-Invasive Marker to Determine Brain Amyloid Status. Journal of Alzheimer's Disease, 100(s1), S131-S152. https://doi.org/10.3233/jad-240631
Vancouver
Poudel P, Frost SM, Eslick S, Sohrabi HR, Taddei K, Martins RN, et al. Hyperspectral Retinal Imaging as a Non-Invasive Marker to Determine Brain Amyloid Status. Journal of Alzheimer's Disease. 2024;100(s1):S131-S152. doi:10.3233/jad-240631
BibTeX
@article{Poudel2024,
author = {Poudel, Purna and Frost, Shaun M and Eslick, Shaun and Sohrabi, Hamid R and Taddei, Kevin and Martins, Ralph N and Hone, Eugene},
title = {Hyperspectral Retinal Imaging as a Non-Invasive Marker to Determine Brain Amyloid Status},
journal = {Journal of Alzheimer's Disease},
year = {2024},
volume = {100},
number = {s1},
pages = {S131--S152},
doi = {10.3233/jad-240631}
}
EUVIMED